title: [Chemoradiotherapy for muscle-invasive cancer: methods, surveillance and results. An update from the cancer committee of the French National Association of Urology].
abstract: Radical cystectomy is the treatment of choice for non-metastatic, muscle infiltrating bladder cancer. However, bladder-sparing approaches can be discussed in carefully selected patients. Bladder-preservation protocols aim to guaranty local control and survival with a functional bladder and a good quality of life. The ideal candidate for bladder-preservation therapy is a patient with a small tumor, stage T2, in whom a complete trans-urethral resection of the bladder tumor is achievable, who has no associated carcinoma in situ or hydronephrosis, and who is medically fit to receive chemotherapy. The 5- and 10-year survival rates for muscle-invasive tumors are approximately 50% and 35%, comparable to the results achievable with cystectomy. Approximately 80% of long-term survivors will preserve a native bladder, and approximately 75% of them will have a normal-functioning bladder.
authors.affiliation: Département d'urologie, institut Arnault-Tzanck, avenue du Dr-Donat, 06700 Saint-Laurent-du-Var, France. quintens.h@orange.fr
authors.forename: H
authors.initials: H
authors.lastname: Quintens
authors.forename: M
authors.initials: M
authors.lastname: Roupret
authors.forename: S
authors.initials: S
authors.lastname: Larré
authors.forename: Y
authors.initials: Y
authors.lastname: Neuzillet
authors.forename: G
authors.initials: G
authors.lastname: Pignot
authors.forename: E
authors.initials: E
authors.lastname: Compérat
authors.forename: H
authors.initials: H
authors.lastname: Wallerand
authors.forename: N
authors.initials: N
authors.lastname: Houédé
authors.forename: C
authors.initials: C
authors.lastname: Roy
authors.forename: M
authors.initials: M
authors.lastname: Soulié
authors.forename: C
authors.initials: C
authors.lastname: Pfister
mesh_terms: D059248:Chemoradiotherapy; D015653:Cystectomy; D006801:Humans; D009130:Muscle, Smooth / Q000473:pathology; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D059351:Organ Sparing Treatments; D011879:Radiotherapy Dosage; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000628:therapy*